Mark Purcell
Stock Analyst at Morgan Stanley
(1.04)
# 3,674
Out of 4,884 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $121.90 | -6.48% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $48.30 | +13.87% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $38.18 | +15.24% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $69.45 | +22.39% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $69.17 | +73.49% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $121.90
Upside: -6.48%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $48.30
Upside: +13.87%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $38.18
Upside: +15.24%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $69.45
Upside: +22.39%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $69.17
Upside: +73.49%